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Accrual target was 20 patients for each group with a planned
interim analysis afterw10 patients. For each pilot patient, a
control was randomly selected from 2013; controls were
matched by age, graft source, diagnosis and cell dose.
Implementation of the pilot was the effort of a multi-disci-
plinary team including physicians, mid-level providers,
nurses, clinical pharmacists, data and quality assurance
personnel.
Findings: For the auto and allo MAC groups, interim analysis
revealed that omission of G-CSF led to longer LOS and longer
time to neutrophil engraftment (see Table). The interim
analysis of the allo RIC group appears to be comparable for
the length of stay and neutrophil engraftment.
Discussion: Any cost savings of not using G-CSF are likely to
be offset by the longer duration of post-transplant hospital-
ization and possible increased risks due to longer periods of
neutropenia. Based on our ﬁndings, the pilot has been dis-
continued for auto and allo MAC transplants, where we will
continue to use G-CSF starting on Day +5 to promote
engraftment. This pilot will accrue the planned 20 patients
for allogeneic RIC patients before a ﬁnal analysis is per-
formed.PHARMACY
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Role of the Hematopoietic Cell Transplant Pharmacist in
Development of Program Guidelines
Jeffrey Betcher 1, Travis Shelton 1, James L. Slack 2, Jose Leis 2,
Veena Fauble 2, Lisa Ostrosky Sproat 2, Jeanne Palmer 2, and
Pierre Noel 2. 1 Pharmacy, Mayo Clinic Arizona, Phoenix, AZ;
2Hematology Oncology/Blood and Marrow Transplant, Mayo
Clinic Arizona, Phoenix, AZ
Background: Methotrexate (MTX) is routinely utilized for
prophylaxis of graft versus host disease (GVHD). MTX may
contribute to mucositis and delayed engraftment. Severe
mucositis results in MTX dose reduction, holding day +6 and/
or day + 11, addition of folinic acid (FA), or the use of dexa-
methasone. Delivery of day +11 MTX has been reported to be
important in reducing the risk of aGVHD. FA administration
after MTX doses has been shown to reduce MTX toxicity. In
an effort to reduce the incidence of mucositis to improve the
likelihood of administering day +11 MTX and to provide a
consistent treatment guideline, the Hematopoietic Cell
Transplant (HCT) program director enlisted the help of the
HCT pharmacist to review the data and recommend
guidelines.
Methods: A review of the literature for post-MTX FA use was
performed and presented at an HCT program education
session. FA dosing, time of initiation post MTX, schedule and
number of doses were discussed. The HCT providers agreed
to follow the HCT pharmacist recommendation of FA 10mg/
m2 IV every 6 hours x 3 doses starting 12 hours after each
MTX dose (day +1, +3, +6 and +11) with myeloablative (MA)
conditioning regimens. All patients received tacrolimus. Data
was retrospectively collected in 2013 after the FA guideline
was adopted and compared to consecutive patients receiving
MA regimens from a control group in 2012. The primary
endpoint was administration of full dose day +11 MTX. Sec-ondary endpoints were rates of aGVHD, cGVHD, total
parenteral nutrition (TPN) use, patient controlled analgesia
(PCA) use, transplant-related mortality (TRM), relapse and
overall survival (OS).
Results: The FA group consisted of 27 patients while there
were 31 in the control. Patients in the FA group were more
likely to receive full dose day +11 MTX as compared to con-
trol, 85.2% vs 48.4% (p¼0.0025) and were less likely to
require PCA, 63% vs. 87.1% (p¼0.03). There was no signiﬁcant
difference in rates of TPN use (48.2% vs. 58.1%), grade II-IV
aGVHD at day 100 (50.4% vs. 30.5%), cGVHD (19.9% vs. 27.7%),
cumulative incidence of relapse (10.8% vs. 8.6%), TRM at 1
year (13.1% vs.19.5%) and OS at 1 year (77.9% vs. 75.9%) for the
FA group and control, with a median follow-up of 465 days
and 670 days, respectively.
Discussion: Patients experienced less mucositis and were
more likely to receive full dose day + 11 MTX after
implementation of the FA guideline. This was also sup-
ported by a statistically signiﬁcant decrease in PCA use.
Other endpoints trended in a favorable direction, but did
not reach statistical signiﬁcance. The development and
utilization of the program guideline improved consistency
of care, improved staff satisfaction and decreased patient
discomfort. HCT pharmacists play an important role in the
review of literature and development of program guide-
lines.125
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Background: Anti-thymocyte globulin (ATG) is often
incorporated into allogeneic stem cell transplant (alloHCT)
conditioning regimens to prevent graft-versus-host disease
(GVHD). Literature regarding the effect of ATG on outcomes
is mixed; some data suggests an improvement in GVHD
control with ATG use, but other data shows a reduction in
overall survival, particularly in the reduced intensity
setting. This study evaluates the impact of ATG on infection,
GVHD, relapse, and mortality rates in adult alloHCT
patients.
Methods: A retrospective review of 250 adult alloHCT
patients at our institution (125 unrelated/mismatched
donor recipients received ATG, 125 matched related do-
nors did not) between 2006 and 2013 was performed.
Charts were reviewed for ATG use, demographics, in-
fections (bacterial, viral, fungal), infection source, GVHD,
day-180 relapse, and day-180 mortality. The primary
endpoint was infection rate; secondary endpoints included
mortality and GVHD.
Results: Factors with signiﬁcant impact on infection inci-
dence were conditioning type (Myeloablative (MAC) >
Reduced Intensity (RIC), p¼0.0105), age (p¼0.0245), and
use of ATG (p¼0.0185). MAC was associated with greater
